Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the target of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 3,600 shares, a drop of 64.7% from the January 15th total of 10,200 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.4% of the shares of the stock are short sold.

Pasithea Therapeutics Stock Up 1.4 %

Shares of KTTA stock opened at $1.43 on Thursday. The stock has a 50-day simple moving average of $2.56 and a 200 day simple moving average of $3.66. Pasithea Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $9.25.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.